Download - Glenmark
Download - Glenmark Download - Glenmark
Information in respect of such unclaimed dividend when due for transfer to the said Fund is given below: Financial Year Ended Date of declaration of Dividend Date of transfer to unpaid/ unclaimed dividend account Last date for claiming unpaid Dividend Due date for transfer to IEP Fund 31.03.2004 29.03.2004 29.04.2004 28.04.2011 28.05.2011 31.03.2005 26.04.2005 26.05.2005 25.05.2012 24.06.2012 31.03.2006 31.01.2006 02.03.2006 01.03.2013 31.03.2013 31.03.2007 26.12.2006 25.01.2007 24.01.2014 23.02.2014 31.03.2008 31.10.2007 30.11.2007 29.11.2014 29.12.2014 31.03.2009 25.09.2009 25.10.2009 24.10.2016 23.11.2016 31.03.2010 27.09.2010 27.10.2010 26.10.2017 25.11.2017 Shareholders who have not so far encashed their dividend warrant(s) are requested to seek issue of duplicate warrant(s) by writing to the Company’s Registrar and Transfer Agents, M/s. Karvy Computershare Pvt. Ltd. immediately. Shareholders are requested to note that no claims shall lie against the Company or the said Fund in respect of any amounts which were unclaimed and unpaid for a period of seven years from the dates that they first became due for payment and no payment shall be made in respect of any such claims. m) Reconciliation of Share Capital Audit Report: A Qualified Practicing Company Secretary has carried out Audit every Quarter to reconcile the total admitted Capital with National Securities Depository Limited(NSDL) and Central Depository Services(India) Limited(CDSL) and the total issued and listed Capital. The Audit confirms that the total issued/paid up Capital is in agreement with the aggregate total number of shares in physical form, shares allotted and advised for demat credit but pending execution and the total number of dematerialized shares held with NSDL and CDSL. n) Subsidiary Monitoring Framework: All the Subsidiary Companies of the Company are Board managed with their Boards having the rights and obligations to manage these Companies in the best interest of their stakeholders. The Company nominates its representatives on the Board of subsidiary companies and monitors performance of such Companies and the minutes of the meetings of the Subsidiary Companies are placed before the Companies Board regularly. o) Means of Communication: a) Quarterly/Half Yearly and Annual Financial Results of the Company are published in the Financial Express and Punyanagri newspapers. b) Your Company’s results and official news releases are displayed on the Company’s website. c) All items required to be covered in the Management Discussion & Analysis are included in the Directors’ Report to Members. d) Company has its own website and all the vital information relating to the Company and its products is displayed on its website: www.glenmarkpharma.com. e) Whether presentation made to institutional investors or to the analysts – Yes. Your Company also regularly provides information to the stock exchanges as per the requirements of the Listing Agreements. The Company’s website is updated periodically to include information on new developments and business opportunities of your Company. The Management Discussion and Analysis forms a part of the Annual Report. 9. Company’s Scrip Information: Listing on stock exchanges: The shares of the Company are listed on Bombay Stock Exchange Limited & The National Stock Exchange of India Ltd. o Listing fees for the year 2011-12 have been paid to the Stock Exchanges. Stock Code: 532296 on the BSE o o ISIN No: INE935A01035 Scrip Name GLENMARK PHA - BSE GLENMARK - NSE 44 GLENMARK PHARMACEUTICALS LIMITED
Market Price Data: High, low during each month in last financial year. Performance in comparison to broad based indices namely BSE Sensex. (All figures in Indian Rupees) Months High Low Glenmark BSE Sensex Apr-10 283.85 257.00 269.85 17,558.71 May-10 303.80 253.30 271.35 16,944.63 Jun-10 282.40 248.80 271.20 17,700.90 Jul-10 294.45 261.00 269.55 17,868.29 Aug-10 301.40 263.80 285.70 17,971.12 Sep-10 307.00 279.15 298.50 20,069.12 Oct-10 342.00 292.50 339.80 20,032.34 Nov-10 385.40 325.90 352.75 19,521.25 Dec-10 389.75 340.10 362.70 20,509.09 Jan-11 372.10 296.25 306.75 18,327.76 Feb-11 315.00 241.60 251.80 17,823.40 Mar-11 305.45 255.00 283.60 19,445.22 10. Corporate Identity Number (CIN) Glenmark 400.00 350.00 300.00 250.00 200.00 150.00 100.00 50.00 - Apr-10 May-10 Glenmark Jun-10 Glenmark Vs. BSE SENSEX Jul-10 Aug-10 Sep-10 Oct-10 Nov-10 Dec-10 BSE Months Jan-11 Feb-11 Mar-11 25000 20000 15000 10000 5000 0 BSE Sensex Our Corporate Identity Number (CIN), allotted by Ministry of Company Affairs, Government of India is L24299MH1977PLC019982 and our Company Registration Number is 19982. 11. Plant Locations: The Company’s plants are located at: i) E-37, MIDC Industrial Area, D Road, Satpur, Nasik - 422 007, Maharashtra. ii) Village: Kishanpura, Baddi Nalagarh Road, Tehsil: Nalagarh, Dist. Solan 174101, Himachal Pradesh. iii) Business Unit II, Village Bhattanwala, PO Rajpura, Nalagarh Dist. Solan, Himachal Pradesh. iv) D-42, Plot No. 50, Kundaim Industrial Estate, Kundaim - 403 115, Goa. 12. Outstanding GDR’s/ADR’s/Warrants or any Convertible instruments exercised, date and likely impact on equity: A) The Company had issued 2,27,000 new options under Employees Stock Option Scheme viz. ESOS’ 2003. During the Financial Year 2010-2011, 4,88,300 options were cancelled and 4,34,500 options were exercised. As of 31 March 2011, 19,37,700 options were outstanding and are due for exercise on the following dates: ESOS’ 2003 Date Number of Options April 27, 2011 1,11,500 May 22, 2011 2,000 May 29, 2011 2,500 July 9, 2011 19,650 July 14, 2011 10,950 August 14, 2011 83,300 August 22, 2011 76,200 October 9, 2011 30,900 October 12, 2011 4,200 November 8, 2011 31,600 December 9, 2011 1,57,200 January 9, 2012 1,17,700 February 5, 2012 3,81,950 February 25, 2012 3,500 March 21, 2012 1,58,500 July 9, 2012 19,650 July 14, 2012 21,900 August 22, 2012 52,800 September 24, 2012 11,100 ESOS’ 2003 Date Number of Options October 9, 2012 31,650 December 9, 2012 1,04,800 January 9, 2013 78,800 February 5, 2013 14,100 February 25, 2013 7,000 March 30, 2013 11,600 July 9, 2013 26,200 July14, 2013 32,850 September 24, 2013 22,200 October 9, 2013 42,200 February 5, 2014 18,800 February 25, 2014 10,500 March 30, 2014 23,200 July 14, 2014 43,800 September 24, 2014 33,300 February 25, 2015 14,000 March 30, 2015 34,800 September 24, 2015 44,400 March 30, 2016 46,400 On exercising the convertible options so granted under the ESOS of the Company, the paid-up equity share capital of the Company will increase by a like number of shares. B) The Company had issued 30,000 Zero Coupon Foreign Currency Convertible Bonds of USD 1000 each. i. Convertible at the option of bondholder at any time on or after 11th November, 2007 and prior to the close of business on 29th November, 2010 at a fixed exchange rate of ` 44.94 per 1 USD and the conversion price of ` 582.60 per share of ` 1/- each. Annual Report 2010-2011 45
- Page 35 and 36: Profiles of Directors Mr. Gracias S
- Page 37 and 38: DIRECTORS Mr. D. R. Mehta, Mrs. B.
- Page 39 and 40: 3. Metformin ER Tablets 1000 mg 4.
- Page 41 and 42: ANNEXURE - B Disc losure in the Dir
- Page 43 and 44: Report on Corporate Governance Purs
- Page 45 and 46: 5. Shareholders’/Investors’ Gri
- Page 47: Distribution Schedule as on 31 Marc
- Page 51 and 52: Certification by the Chief Executiv
- Page 53 and 54: Auditors’ Report To, The Members
- Page 55 and 56: (b) The dues outstanding in respect
- Page 57 and 58: Profit and Loss Account (All amount
- Page 59 and 60: Cash Flow Statement (All amounts in
- Page 61 and 62: Schedules annexed to and forming pa
- Page 63 and 64: Schedules annexed to and forming pa
- Page 65 and 66: Schedules annexed to and forming pa
- Page 67 and 68: Schedules annexed to and forming pa
- Page 69 and 70: Schedules annexed to and forming pa
- Page 71 and 72: Schedules annexed to and forming pa
- Page 73 and 74: Schedules annexed to and forming pa
- Page 75 and 76: Schedules annexed to and forming pa
- Page 77 and 78: Schedules annexed to and forming pa
- Page 79 and 80: Schedules annexed to and forming pa
- Page 81 and 82: Additional information as required
- Page 83 and 84: Consolidated Statement of Financial
- Page 85 and 86: Consolidated Statement of Comprehen
- Page 87 and 88: Notes to Consolidated Financial Sta
- Page 89 and 90: the foreign entity and translated i
- Page 91 and 92: The Group’s internal drug develop
- Page 93 and 94: Financial liabilities are recognise
- Page 95 and 96: In those cases where the possible o
- Page 97 and 98: NOTE B - BASIS OF CONSOLIDATION The
Information in respect of such unclaimed dividend when due for transfer to the said Fund is given below:<br />
Financial<br />
Year Ended<br />
Date of declaration<br />
of Dividend<br />
Date of transfer to<br />
unpaid/ unclaimed<br />
dividend account<br />
Last date for<br />
claiming unpaid<br />
Dividend<br />
Due date for transfer<br />
to IEP Fund<br />
31.03.2004 29.03.2004 29.04.2004 28.04.2011 28.05.2011<br />
31.03.2005 26.04.2005 26.05.2005 25.05.2012 24.06.2012<br />
31.03.2006 31.01.2006 02.03.2006 01.03.2013 31.03.2013<br />
31.03.2007 26.12.2006 25.01.2007 24.01.2014 23.02.2014<br />
31.03.2008 31.10.2007 30.11.2007 29.11.2014 29.12.2014<br />
31.03.2009 25.09.2009 25.10.2009 24.10.2016 23.11.2016<br />
31.03.2010 27.09.2010 27.10.2010 26.10.2017 25.11.2017<br />
Shareholders who have not so far encashed their dividend warrant(s) are requested to seek issue of duplicate<br />
warrant(s) by writing to the Company’s Registrar and Transfer Agents, M/s. Karvy Computershare Pvt. Ltd.<br />
immediately. Shareholders are requested to note that no claims shall lie against the Company or the said Fund<br />
in respect of any amounts which were unclaimed and unpaid for a period of seven years from the dates that they<br />
first became due for payment and no payment shall be made in respect of any such claims.<br />
m) Reconciliation of Share Capital Audit Report:<br />
A Qualified Practicing Company Secretary has carried out Audit every Quarter to reconcile the total admitted<br />
Capital with National Securities Depository Limited(NSDL) and Central Depository Services(India) Limited(CDSL)<br />
and the total issued and listed Capital. The Audit confirms that the total issued/paid up Capital is in agreement<br />
with the aggregate total number of shares in physical form, shares allotted and advised for demat credit but<br />
pending execution and the total number of dematerialized shares held with NSDL and CDSL.<br />
n) Subsidiary Monitoring Framework:<br />
All the Subsidiary Companies of the Company are Board managed with their Boards having the rights and<br />
obligations to manage these Companies in the best interest of their stakeholders. The Company nominates its<br />
representatives on the Board of subsidiary companies and monitors performance of such Companies and the<br />
minutes of the meetings of the Subsidiary Companies are placed before the Companies Board regularly.<br />
o) Means of Communication:<br />
a) Quarterly/Half Yearly and Annual Financial Results of the Company are published in the Financial Express<br />
and Punyanagri newspapers.<br />
b) Your Company’s results and official news releases are displayed on the Company’s website.<br />
c) All items required to be covered in the Management Discussion & Analysis are included in the Directors’<br />
Report to Members.<br />
d) Company has its own website and all the vital information relating to the Company and its products is<br />
displayed on its website: www.glenmarkpharma.com.<br />
e) Whether presentation made to institutional investors or to the analysts – Yes.<br />
Your Company also regularly provides information to the stock exchanges as per the requirements of<br />
the Listing Agreements. The Company’s website is updated periodically to include information on new<br />
developments and business opportunities of your Company.<br />
The Management Discussion and Analysis forms a part of the Annual Report.<br />
9. Company’s Scrip Information:<br />
<br />
Listing on stock exchanges: The shares of the Company are listed on Bombay Stock Exchange Limited & The<br />
National Stock Exchange of India Ltd.<br />
o<br />
Listing fees for the year 2011-12 have been paid to the Stock Exchanges.<br />
<br />
Stock Code: 532296 on the BSE<br />
o<br />
o<br />
ISIN No: INE935A01035<br />
Scrip Name<br />
GLENMARK PHA - BSE<br />
GLENMARK - NSE<br />
44<br />
GLENMARK PHARMACEUTICALS LIMITED
Change language